Webinar: Generation of a Dual-Function Multi-engager Antibody for Simultaneous Targeting NK Cells and Tumor Cells

{{$t("Scan and Share")}}
{{$t("Scan the qr to open and share in mobile, or")}} {{$t("Click Here")}} {{$t("to copy the shareable link")}} http://t2u.asia/e/43152
Online Event
Map

📍 Share This Location


Event {{$t("Expired")}}

{{$t("More info on this event")}}

Details

Date 11:00 AM EDT | May 22, 2025

Register for Creative Biolabs' Webinar


The relentless pursuit of innovative cancer immunotherapies has unveiled natural killer (NK) cells as formidable agents in the fight against malignancies. While these innate immune cells possess inherent tumor-killing capabilities, their full potential remains constrained by regulatory mechanisms and tumor evasion strategies. At the forefront of this research stands ADAM17, a membrane-associated protease that functions as both a negative regulatory checkpoint in NK cells and a tumor-associated antigen overexpressed in various malignancies. Creative Biolabs is honored to invite Dr. Bruce Walcheck to introduce the Targeted ADAM17 Blocker and Killer (TABK), an ingenious multi-engager antibody complex that simultaneously enhances NK cell proliferation while directing these empowered immune cells to engage and eliminate ADAM17-expressing tumor cells. Join us to explore how this innovative approach leverages ADAM17's unique dual role to create a potent immunotherapeutic strategy with promising implications for cancer treatment.


During this webinar, we will discuss the following key points:


NK cell-mediated natural cytotoxicity and antibody-dependent cellular cytotoxicity (ADCC)

Utilizing NK cells to kill cancer cells

ADAM17, a membrane-associated protease expressed by NK cells

ADAM17 functions as a negative regulatory checkpoint in NK cells and is a tumor-associated antigen

ADAM17 inhibition by the mAb Medi-1 enhances NK cells activation and proliferation

Development of the multi-engager antibody complex Targeted ADAM17 Blocker and Killer (TABK)

TABK selectively blocks ADAM17 in NK cells and synergizes with IL-15 stimulation to enhance NK cell activation and proliferation

TABK engages ADAM17 overexpressed by various malignancies, linking NK cells to tumor cells to mediate their killing

{{$t("Terms and Conditions")}}

During this webinar, we will discuss the following key points:


NK cell-mediated natural cytotoxicity and antibody-dependent cellular cytotoxicity (ADCC)

Utilizing NK cells to kill cancer cells

ADAM17, a membrane-associated protease expressed by NK cells

ADAM17 functions as a negative regulatory checkpoint in NK cells and is a tumor-associated antigen

ADAM17 inhibition by the mAb Medi-1 enhances NK cells activation and proliferation

Development of the multi-engager antibody complex Targeted ADAM17 Blocker and Killer (TABK)

TABK selectively blocks ADAM17 in NK cells and synergizes with IL-15 stimulation to enhance NK cell activation and proliferation

TABK engages ADAM17 overexpressed by various malignancies, linking NK cells to tumor cells to mediate their killing

The organizer did not describe themself much.
Scan & Share
http://t2u.asia/e/43152 

Webinar: Generation of a Dual-Function Multi-engager Antibody for Simultaneous Targeting NK Cells and Tumor Cells

Online Event

Event Expired

Date 11:00 AM EDT | May 22, 2025

Register for Creative Biolabs' Webinar


The relentless pursuit of innovative cancer immunotherapies has unveiled natural killer (NK) cells as formidable agents in the fight against malignancies. While these innate immune cells possess inherent tumor-killing capabilities, their full potential remains constrained by regulatory mechanisms and tumor evasion strategies. At the forefront of this research stands ADAM17, a membrane-associated protease that functions as both a negative regulatory checkpoint in NK cells and a tumor-associated antigen overexpressed in various malignancies. Creative Biolabs is honored to invite Dr. Bruce Walcheck to introduce the Targeted ADAM17 Blocker and Killer (TABK), an ingenious multi-engager antibody complex that simultaneously enhances NK cell proliferation while directing these empowered immune cells to engage and eliminate ADAM17-expressing tumor cells. Join us to explore how this innovative approach leverages ADAM17's unique dual role to create a potent immunotherapeutic strategy with promising implications for cancer treatment.


During this webinar, we will discuss the following key points:


NK cell-mediated natural cytotoxicity and antibody-dependent cellular cytotoxicity (ADCC)

Utilizing NK cells to kill cancer cells

ADAM17, a membrane-associated protease expressed by NK cells

ADAM17 functions as a negative regulatory checkpoint in NK cells and is a tumor-associated antigen

ADAM17 inhibition by the mAb Medi-1 enhances NK cells activation and proliferation

Development of the multi-engager antibody complex Targeted ADAM17 Blocker and Killer (TABK)

TABK selectively blocks ADAM17 in NK cells and synergizes with IL-15 stimulation to enhance NK cell activation and proliferation

TABK engages ADAM17 overexpressed by various malignancies, linking NK cells to tumor cells to mediate their killing

Terms and Condition

During this webinar, we will discuss the following key points:


NK cell-mediated natural cytotoxicity and antibody-dependent cellular cytotoxicity (ADCC)

Utilizing NK cells to kill cancer cells

ADAM17, a membrane-associated protease expressed by NK cells

ADAM17 functions as a negative regulatory checkpoint in NK cells and is a tumor-associated antigen

ADAM17 inhibition by the mAb Medi-1 enhances NK cells activation and proliferation

Development of the multi-engager antibody complex Targeted ADAM17 Blocker and Killer (TABK)

TABK selectively blocks ADAM17 in NK cells and synergizes with IL-15 stimulation to enhance NK cell activation and proliferation

TABK engages ADAM17 overexpressed by various malignancies, linking NK cells to tumor cells to mediate their killing

 
The organizer did not describe themself much.
Event Links
http://t2u.asia/e/43152 
Follow This Event

{{$t("Check Shipping Status")}}

{{$t("Key in your tracking number to check shipping status")}}